Vidya Raghavan, Athwal Ruvinder, Huissoon Aarnoud P, Baretto Richard L, Thirumala Krishna Mamidipudi
Department of Breast Surgery, Royal Wolverhampton Hospital, Wolverhampton, UK.
Department of Allergy and Immunology, Heart of England NHS Foundation Trust, Birmingham, UK.
Indian J Cancer. 2019 Jul-Sep;56(3):269-270. doi: 10.4103/ijc.IJC_139_18.
Sentinel lymph node biopsy (SLNB) was introduced in the 1990s, as a minimally invasive procedure for staging the axilla with less morbidity to the traditional axillary lymph node dissection and is now standard management of the axilla in the early breast cancer. SLNB using the combined technique of blue dye and radioisotope is currently the recommended method for lymphatic mapping, and studies have shown high identification rates (IR) (>95%) and low false-negative rates (FNR) 5-10%. However, there are several reports raising awareness regarding patent blue V dye-induced peri-operative anaphylaxis. The main aim of this article is to highlight the emergence of patent blue dye as a new allergen and present evidence regarding the utility of alternative safer methods of evaluation of early breast cancer without compromising IR.
前哨淋巴结活检（SLNB）于20世纪90年代被引入，作为一种微创方法用于腋窝分期，与传统腋窝淋巴结清扫相比，其发病率更低，目前是早期乳腺癌腋窝的标准治疗方法。使用蓝色染料和放射性同位素联合技术的SLNB目前是推荐的淋巴管造影方法，研究表明其识别率（IR）高（>95%）且假阴性率（FNR）低（5-10%）。然而，有几份报告提高了人们对专利蓝V染料引起围手术期过敏反应的认识。本文的主要目的是强调专利蓝染料作为一种新过敏原的出现，并提供有关在不影响识别率的情况下评估早期乳腺癌的替代更安全方法实用性的证据。
